Get the Stockscreener App
5.70
5.16%
-0.31
After Hours:
5.75
0.05
+0.88%
Protara Therapeutics Inc stock is traded at $5.70, with a volume of 699.80K.
It is down -5.16% in the last 24 hours and up +7.55% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$6.01
Open:
$6.06
24h Volume:
699.80K
Relative Volume:
0.91
Market Cap:
$294.30M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-2.0213
EPS:
-2.82
Net Cash Flow:
$-35.26M
1W Performance:
+2.15%
1M Performance:
+7.55%
6M Performance:
+74.85%
1Y Performance:
-8.80%
1-Day Range:
$5.52
$6.125
1-Week Range:
$5.52
$6.37
52-Week Range:
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.70 | 310.30M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Acorn Capital Advisors LLC Acquires 472,315 Shares of Protara Therapeutics, Inc. $TARA - MarketBeat
Protara Therapeutics completes $75 million stock offering - MSN
Protara Therapeutics Completes $75 Million Stock Offering - TipRanks
Protara therapeutics raises $75 million in public offering - Investing.com
Protara Therapeutics Closes $75 Million Public Offering - marketscreener.com
Protara therapeutics raises $75 million in public offering By Investing.com - Investing.com India
Protara Announces Closing of $75 Million Public Offering - The Manila Times
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Protara announces proposed public offering - MSN
Is Protara Therapeutics Inc a good long term investmentOptions Trading Strategies & High Return Trading Strategies - earlytimes.in
Protara Therapeutics: Stock Offer Takes the Spotlight - StocksToTrade
Protara Therapeutics (TARA) Stock Plunges After $75 Million Offering: Latest Trial Data, Analyst Targets and Outlook as of December 5, 2025 - ts2.tech
Protara Prices $75 Mln Offering To Advance TARA-002 And Broader Pipeline - Nasdaq
Biotech co Protara slides on $75 mln share sale - TradingView — Track All Markets
Protara Therapeutics Shares Sink 16% After $75 Mln Public Offering - Nasdaq
Protara Therapeutics (Nasdaq: TARA) prices 13,043,479-share, $75M public deal - Stock Titan
Protara Therapeutics (TARA) Launches $75M Public Offering - GuruFocus
Protara Therapeutics Prices $75 Million Share Offering - marketscreener.com
Will Protara Therapeutics Inc. (1KPA) stock benefit from sector leadershipJuly 2025 Price Swings & Accurate Trade Setup Notifications - Newser
Protara Therapeutics prices $75 million public offering By Investing.com - Investing.com Nigeria
TARA Stock Offering Priced at Lower End of Target Range - GuruFocus
Protara Therapeutics prices $75 million public offering - Investing.com
Key Managers Announced for TARA Offering - GuruFocus
Protara Announces Pricing of $75 Million Public Offering - The Manila Times
Protara prices public offering of 13.04 million shares at $5.75 each - marketscreener.com
Protara Announces Pricing of $75 Million Public Offering - GlobeNewswire Inc.
Protara Therapeutics stock tumbles after $75M public offering By Investing.com - Investing.com Australia
Protara Therapeutics Launches Offering of Securities - marketscreener.com
Protara Therapeutics announces $75 million public offering - Investing.com
Protara Therapeutics stock tumbles after $75M public offering - Investing.com
Protara Therapeutics announces $75 million public offering By Investing.com - Investing.com South Africa
Protara Announces Proposed Public Offering - The Manila Times
Protara Therapeutics Announces $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Protara Therapeutics (Nasdaq: TARA) starts $75M stock and pre-funded warrant sale - Stock Titan
Protara Therapeutics (NASDAQ:TARA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Protara’s cell therapy touts BCG-naïve treatment potential in Phase II - Yahoo Finance
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients - marketscreener.com
Protara Therapeutics: End Of 2025 Proving Eventful Indeed (NASDAQ:TARA) - Seeking Alpha
Why Protara Therapeutics Inc. (1KPA) stock is listed among top recommendationsEarnings Overview Report & Daily Stock Trend Reports - Newser
Protara Therapeutics (NASDAQ:TARA) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright & Co. Reiterates Protara Therapeutics (TARA) Buy Recommendation - Nasdaq
TARA: HC Wainwright & Co. Reiterates 'Buy' Rating with $23 Targe - GuruFocus
TARA: TARA-002 shows 69% six-month CR and strong safety in BCG naive NMIBC, advancing to registrational trial - TradingView — Track All Markets
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):